Compare BridgeBio Pharma Inc (BBIO) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Verisign, Inc. — how do they compare? BridgeBio Pharma Inc trades at $83.86 (market cap $16.36B), while Verisign, Inc. trades at $287.62 (market cap $26.00B). The key difference: Verisign, Inc. is the larger of the two by market cap, and Verisign, Inc. pays a 1.13% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | VRSN | |
|---|---|---|
Market Cap | $16.36B | $26.00B |
Sector | Health | Technology |
52-Week High | $90.17 | $310.00 |
52-Week Low | $47.29 | $211.49 |
Enterprise Value | $18.14B | $27.31B |
Dividend Yield | — | 1.13% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
